Based on these studies, a phase I study was conducted with CD137L-expressing DCs that were pulsed with a peptide mix of EBV LMP1, LMP2, and LMP2A as a vaccination for NPC patients. Here, PDLIM7 is linked to nasopharyngeal carcinoma.